Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

References

• Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309–318 (1999).
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6(10), 715–727 (2006).
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295–307 (2006).
   PubMed Web of Science ®Google Scholar
• Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that cooperate with innate immunity. Trends Immunol. (8), 352–357 (2006).
   Google Scholar
• Janeway CAJr, Metzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197–216 (2002).
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Exp. Rev. Vaccines 8(1), 51–66 (2009).
   PubMed Web of Science ®Google Scholar
• Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
   PubMed Web of Science ®Google Scholar
• Bishop JM. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52, 301–354 (1983).
   PubMed Web of Science ®Google Scholar
• Weinberg RA. Tumor suppressor genes. Science 254(5035), 1138–1146 (1991).
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361(25), 2449–2460 (2009).
   PubMed Web of Science ®Google Scholar
• Baccelli I, Trumpp, A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198(3), 281–293 (2012).
   PubMed Web of Science ®Google Scholar
• Kitano H. Cancer robustness: tumor tactics. Nature 426(6963), 125 (2003).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmark of cancer. Cell 100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove PGarbi N et al. Bone marrow as a priming site for T cell responses to blood-borne antigens. Nat. Med. 9(9), 1151–1157 (2003).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann. Rev. Immunol. 22, 745–763 (2004).
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger ACamus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654–2666 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki A, Masuda ANagata H et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J. Pathol. 196(1), 37–43 (2002).
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298–306 (2012).
   PubMed Web of Science ®Google Scholar
• Wagner P, Koch MNummer D et al. Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann. Surg. Oncol. 15(8), 2310–2317 (2008).
   PubMed Web of Science ®Google Scholar
• Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol. Immunother. 51(10), 574–582 (2002).
   PubMed Web of Science ®Google Scholar
• Bonertz A, Weitz JPietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119(11), 3311–3321 (2009).
   PubMed Web of Science ®Google Scholar
• Salama P, Philipps MGrieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27(2), 186–192 (2009).
   PubMed Web of Science ®Google Scholar
• Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J. of Gastroenterology 17(26), 3092–3100 (2011).
   PubMed Web of Science ®Google Scholar
• Blatner NR, Bonertz ABeckhove P et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl Acad. Sci. USA 107(14), 6430–6435 (2010).
   PubMed Web of Science ®Google Scholar
• Hanna MG, Pollack VA, Peters LC, Hoover HC. Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines. Cancer 49(4), 659–664 (1982).
   PubMed Web of Science ®Google Scholar
• Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int. J. Cancer 37(4), 569–577 (1986).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hübsch D. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between the parental tumor line and its metastasizing variant. Int. J. Cancer 23(2), 245–252 (1979).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin. Exp. Metastasis 5(2), 147–156 (1987).
   PubMed Web of Science ®Google Scholar
• Angelova M, Charoentong P, Hackl H, Fischer M, Galon J, Trajanoski Z. Immunogenicity of the colorectal mutanome. Abstract 089 from the Abstract Book 2013 of the 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, 14–16 May 2013.
   Google Scholar
• Lindenmann J, Klein PA. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126(1), 93–108 (1967).
   PubMed Web of Science ®Google Scholar
• Russel SJ. RNA viruses as virotherapy agents. Cancer Gene Ther. 9(12), 961–966 (2002).
   PubMed Web of Science ®Google Scholar
• Cassel WA, Garret RE. Newcastle disease virus as an antineoplastic agent. Cancer 18, 863–868 (1965).
   PubMed Web of Science ®Google Scholar
• Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated post-surgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother. 9(4), 169–171 (1992).
   PubMedGoogle Scholar
• Tanaka N, Sivanandham M, Wallack MK. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-α increases the survival of mice bearing syngeneic colon adenocarcinoma. J Immunother Emphasis Tumor Immunol 16(4), 283–293 (1994).
   PubMed Web of Science ®Google Scholar
• Jack AM, Aydin N, Montenegro G, Alam K, Wallack M. A novel dendritic cell-based cancer vaccine produces promising results in a syngeneic CC-36 murine colon adenocarcinoma model. J. Surg. Res. 139(2), 164–169 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Viral xenogenization of intact tumor cells. Adv. Cancer Res. 30, 279–299 (1979).
   PubMedGoogle Scholar
• Schirrmacher V, von Hoegen P. Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines. Vaccine Res. 2, 183–196 (1993).
   Google Scholar
• Von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon α/beta. Cell. Immunol. 126(1), 80–90 (1990).
   PubMed Web of Science ®Google Scholar
• Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur. J. Immunol. 23(10), 2592–2596 (1993).
   PubMed Web of Science ®Google Scholar
• Hoover HcJr, Brandhorst JSPeters LC et al. Adjuvant active-specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390–399 (1993).
   PubMed Web of Science ®Google Scholar
• Ali-El-Dein B, Barakat TS, Nabeeh A, Ibrahiem el-HI. Weekly intra vesicular bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: an approach to decrease BCG toxicity. Urol. Ann. 5(2), 103–108 (2013).
   PubMedGoogle Scholar
• Imler IL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol. 11(7), 304–311 (2001).
   PubMed Web of Science ®Google Scholar
• Shima F, Uto T, Akaji M. Synergistic stimulation of antigen-presenting cells via TLR by combining CpG ODN and poly(gamma-glutamic acid)-based nanoparticles as vaccine adjuvants. Bioconjug. Chem. 24(6), 926–933 (2013).
   PubMed Web of Science ®Google Scholar
• Jarahian M, Watzl CFournier P et al. Activation of natural killer cells by Newcastle-disease virus hemagglutinin-neuraminidase. J. Virol. 83(16), 8108–8121 (2009).
   PubMed Web of Science ®Google Scholar
• Gatti G, Nunez NGNocera DA et al. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-ß production capable of improving dendritic cell function. Eur. J. Immunol. 43(7), 1849–1861 (2013).
   PubMed Web of Science ®Google Scholar
• Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene 1 and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int. J. Oncol. 40(1), 287–298 (2012).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Haas CBonifer R et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6(1), 63–73 (1999).
   PubMed Web of Science ®Google Scholar
• Termeer CC, Schirrmacher V, Bröcker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther. 7(2), 316–323 (2000).
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MGJr et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23(17–18), 2379–2387 (2005).
   PubMed Web of Science ®Google Scholar
• Ockert D, Schirrmacher VBeck N et al. Newcastle disease virus-infected autologous intact tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2(1), 21–28 (1996).
   PubMed Web of Science ®Google Scholar
• Ahlert T, Sauerbrei WBastert G et al. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J. Clin. Oncol. 15(4), 1354–1366 (1997).
   PubMed Web of Science ®Google Scholar
• Steiner HH, Bonsanto MMBeckhove P et al. Anti-tumor vaccination of patients with glioblastoma multiforme in a case-control study: feasibility, safety and clinical benefit. J. Clin. Oncol. 22(21), 4272–4281 (2004).
   PubMed Web of Science ®Google Scholar
• Kaech SM, Ahmet R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat. Immunol. 2(5), 415–422 (2001).
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol. 10(3), 193–200 (2010).
   PubMed Web of Science ®Google Scholar
• Schluns KSLefrancois, L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3(4), 269–279 (2003).
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Kanai TTakahara M et al. Bone marrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 62(8), 1142–1152 (2013).
   PubMed Web of Science ®Google Scholar
• Snell LM, Lin GH, Watts TH. IL-15 dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of Il-15. J. Immunol. 188(12), 5915–5923 (2012).
   PubMed Web of Science ®Google Scholar
• Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naïve, effector and memory CD8+ T cells. J. Exp. Med. 194(7), 953–966 (2001).
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove PBai L et al. Therapy of human tumors in NOD/SCID mice with patient-derived re-activated memory T cells from bone marrow. Nat. Med. 7(4), 452–458 (2001).
   PubMed Web of Science ®Google Scholar
• Beckhove P, Feuerer MDolenc M et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest. 114(1), 67–76 (2004).
   PubMed Web of Science ®Google Scholar
• Hsu SC, Wang LTYao CL et al. Mesenchymal stem cells promote neutrophil activation by inducing IL-17 production in CD4+ CD45RO+ T cells. Immunobiol. 218(1), 90–95 (2013).
   PubMed Web of Science ®Google Scholar
• Duffy D, Perrin HAbadie V et al. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. Immunity 37(5), 917–929 (2012).
   PubMed Web of Science ®Google Scholar
• Cavanagh LL, Bonasio RMazo IB et al. Activation of bone marrow- resident memory T cells by circulating, antigen-bearing dendritic cells. Nat. Immunol. 6(10), 1029–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Feuerer MFournier P et al. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol. Med. 9(12), 526–534 (2003).
   PubMed Web of Science ®Google Scholar
• Murao A, Oka YTsuboi A et al. High frequencies of less differentiated and more proliferative WT1-specific T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ. Cancer Sci. 101(4), 848–854 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang X, Dong HLin W et al. Human bone marrow: a reservoir for ‘enhanced effector memory’ CD8+ T cells with potent recall function. J. Immunol. 177(10), 6730–6737 (2006).
   PubMed Web of Science ®Google Scholar
• Na IK, Letsch AGuerreiro M et al. Human bone marrow as a source to generate CMV-specific CD4+ T cells with multifunctional capacity. J. Immunother. 32(9), 907–913 (2009).
   PubMed Web of Science ®Google Scholar
• Schmitz-Winnenthal FH, Volk C, Z'graggen K et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 65(21), 10079–10087 (2005).
   PubMed Web of Science ®Google Scholar
• Beckhove P, Schirrmacher V. Local tumor growth and spontaneous systemic T cell responses in cancer patients: a paradox and puzzle. In: Innate and Adaptive Immunity in the Tumor Microenvironment. Yefenof E (Ed.). Springer, New York, NY, USA, 53–76 (2008).
   Google Scholar
• Sommerfeldt N, Schütz F, Sohn C et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 66(16), 8258–8265 (2006).
   PubMed Web of Science ®Google Scholar
• Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher, V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 21(4), 685–694 (2002).
   PubMed Web of Science ®Google Scholar
• Mahnke Y, Schwendemann J, Beckhove P, Schirrmacher, V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115(3), 325–336 (2005).
   PubMed Web of Science ®Google Scholar
• Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 21(1), 85–93 (2002).
   PubMed Web of Science ®Google Scholar
• Von der Ohe M, Altstaed J, Gross U, Rink L. Human neutrophils produce macrophage inhibitory protein-1 beta but not type I interferons in response to viral stimulation. J. Interferon Cytokine Res. 21(4), 241–247 (2001).
   PubMed Web of Science ®Google Scholar
• Mikhak Z, Fleming CMMedoff BD et al. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J. Immunol. 176(8), 4959–4967 (2006).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and III colon cancer: a randomized trial. Lancet 353(9150), 345–350 (1999).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Jurianz K, Roth Ch, Griesbach A, Bonifer R, Zawatzky R. Tumor stimulator cell modification by infection with Newcastle disease virus: Analysis of effects and mechanism in MLTC-CML cultures. Int. J. Oncol. 14(2), 205–215 (1999).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Schulz O, Diebold SSChen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028), 887–892 (2005).
   PubMed Web of Science ®Google Scholar
• Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23(19), 2439–2453 (2005).
   PubMed Web of Science ®Google Scholar
• Fournier P, Arnold A, Schirrmacher V. Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle disease virus. J. BUON 14(Suppl. 1), 111–122 (2009).
   Google Scholar
• Fournier P, Arnold A, Wilden H, Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int. J. Oncol. 40(3), 840–850 (2012).
   PubMed Web of Science ®Google Scholar
• Kalinski P, Nakamura YWatchmaker P et al. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 36(1–3), 137–146 (2006).
   Web of Science ®Google Scholar
• Dolan BP, Gibbs KDJr, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by „cross-dressed' dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 176(3), 1447–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T cell activation after viral infection. Nature 471(7340), 629–632 (2011).
   PubMed Web of Science ®Google Scholar
• Dolan BP, Gibbs KDJr, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J. Immunol. 177(9), 6018–6024 (2006).
   PubMed Web of Science ®Google Scholar
• Petersen TR, Sika-Paotonu D, Knight DA et al. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS ONE 6(3), e17657 (2011).
   PubMed Web of Science ®Google Scholar
• Schwendemann J, Choi C, Schirrmacher V, Beckhove P. Dynamic differentiation of activated human peripheral blood CD8+ and CD4+ effector memory T cells. J. Immunol. 175(3), 1433–1439 (2005).
   PubMed Web of Science ®Google Scholar
• Cieri N, Camisa BCocchiarella F et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naïve precursors. Blood 121(4), 573–584 (2013).
   PubMed Web of Science ®Google Scholar
• Li G, Yang QZhu Y et al. T-bet and Eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells. PLoS ONE 8(6), e67401 (2013).
   PubMed Web of Science ®Google Scholar
• Kohler ME, Hallett WHChen QR et al. Early expression of stem-cell associated genes within the CD8+ compartment after treatment with a tumor vaccine. Cell. Immunol. 265(1), 65–73 (2010).
   PubMed Web of Science ®Google Scholar
• DiRosa F, Santoni A. Memory T cell competition for bone marrow seeding. Immunology 108(3), 296–304 (2003).
   PubMed Web of Science ®Google Scholar
• Braumüller H, Wieder TBrenner E et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494(7437), 361–367 (2013).
   PubMed Web of Science ®Google Scholar
• Merika E, Saif MW, Katz A, Syrigos K, Morse M. Colon cancer vaccines: an update. In vivo 24(5), 607–628 (2010).
   PubMed Web of Science ®Google Scholar
• Rao B, Han MWang L et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J. Transl. Med. 9, 17 (2011).
   Google Scholar
• De Weger VA, Turksma AWVoorham QJM et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin. Cancer Res. 18(3), 882–889 (2011).
   PubMed Web of Science ®Google Scholar
• Schulze T, Kemmner WWeitz J et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61–69 (2009).
   PubMed Web of Science ®Google Scholar
• Schlag P, Manasterski MGerneth T et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. 35(5), 325–330 (1992).
   PubMed Web of Science ®Google Scholar
• O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96(19), 1420–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Liang W, Wang HSun TM et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9(3), 495–498 (2003).
   PubMed Web of Science ®Google Scholar
• Park MS, García-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 77(17), 9522–9532 (2003).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Fournier P. Danger signals in tumor cells: a risk factor for autoimmune disease? Exp. Rev. Vaccines 9(4), 347–350 (2010).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296–306 (2005).
   PubMed Web of Science ®Google Scholar
• Wu YG, Wu GZWang L et al. Tumor cell lysate-pulsed dendritic cells induce a T-cell response against colon cancer in vitro and in vivo. Med. Oncol. 27(3), 736–742 (2010).
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Thiel E. Clinical and immunological responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. 12(10), 3064–3069 (2006).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CSShore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Bach P, Abel THoffmann C et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 73(2), 865–874 (2013).
   PubMed Web of Science ®Google Scholar
• Duarte S, Momier DBaque P et al. Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells 31(3), 423–432 (2013).
   PubMed Web of Science ®Google Scholar
• Ileana E, Champiat S, Soria J.C. Immune-Checkpoints: the new anti-cancer immunotherapies. Bull. Cancer 100(6), 601–610 (2013).
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs K.S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br. J. Cancer 108(8), 1560–1565 (2013).
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FSBrahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Liefers GJ, Cleton-Jansen AM, van de Velde CJ et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med. 339(4), 223–228 (1998).
   PubMed Web of Science ®Google Scholar